We secure approvals – US FDA and CE marking before the end of 2020
BioSpectrum Asia|March 2020
Incorporated in early 2018, Pune, India based health tech startup In-Med Prognostics has developed an artificial intelligence (AI) based brain health diagnostic and prognostic tool called NeuroShield, which is one-of-its-kind in India. It is a cloud-based clinical decision support tool for neurological disorders. The tool utilizes three dimensional (3D) based magnetic resonance images to their full potential by extracting data and providing volumetric analysis for the brain and its various structures. The analysis of NeuroShield enables actionable, quantitative, objective decision making to the neuro-physicians for differential diagnosis. To gather more information on this innovative product, BioSpectrum spoke to Dr Latha Poonamallee, Cofounder & Chairperson, In-Med Prognostics, Pune in India. Edited Excerpts;
Dr Manbeena Chawla
We secure approvals – US FDA and CE marking before the end of 2020

What are the major features of NeuroShield that make it one of a kind in India?

NeuroShield is the first such product to be using AI in brain volumetry outside of the US and EU and the first in India. It is also the first to use an ethnicity/ geography-based reference range. One of the reasons the other products were not adopted here in India was because the reference data was not relevant but this approach of ethnicity-based reference is a new approach to using data analytics relevant for different populations. Finally, our cost structure makes it affordable and accessible to all. We spent close to 18 months in the actual development of this product and another year was put in for preparation and research. The company was formed in Jan 2018 and the product was launched in Jan 2020.

What is your current reach and how do you plan to further enhance it?

Right now, we have partnered with over 15 hospitals in major and minor cities. Some of these hospitals like Max Neuro are a chain hospital with 14 hospitals and similarly, Aarthi Scans has over 25 centers. To name a few more, we are associated with hospitals and screening centres such as Sahyadri Hospital, Deenanath Mangeshkar Hospital, NM Medical, P.H diagnostic centre and Noble Hospital. To fulfill our social mission, we also plan to expand our presence in Tier 2 and Tier 3 cities. We also plan to expand our global footprint. We are in talks with hospitals in Dubai, Philippines, Indonesia and Australia. We are also in touch with Abu Dhabi government agency about opening an office in their innovation center.

How do you intend to contribute to mental healthcare in India?

This story is from the March 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the March 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView All
Korea designs sweat resistant wearable robot sensor
BioSpectrum Asia

Korea designs sweat resistant wearable robot sensor

New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.

time-read
1 min  |
March 2024
Why Singapore is Deep Tech Innovation Frontrunner
BioSpectrum Asia

Why Singapore is Deep Tech Innovation Frontrunner

Move over Artificial Intelligence Al) and Machine Learning ML), there's a new technology on the block Deep Tech. This latest technology holds immense potential for the life sciences industry, and Singapore is leaving no stone unturned in becoming a deep tech hub. From strategic investments to collaborative initiatives and a supportive regulatory environment, read on to find out about the country's initiatives in becoming a deep tech superpower.

time-read
4 mins  |
March 2024
Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?
BioSpectrum Asia

Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?

The World Health Organization (WHO) has taken a significant stride in the battle against Tuberculosis (TB) by introducing shorter drug regimens, aiming to curb a disease that claims countless lives globally. This innovative approach addresses the urgent need for more efficient treatments, especially in regions where TB's toll is highest. With traditional therapies often posing risks to liver health, these shortened regimens offer hope, minimising such concerns while enhancing treatment adherence.

time-read
5 mins  |
March 2024
How pharma is finally researching issues that primarily affect women
BioSpectrum Asia

How pharma is finally researching issues that primarily affect women

Pharma is now concentrating on problems that impact women. Female participation will now directly contribute to cures for diseases that affect them, since more studies specifically targeted at women are planned.

time-read
8 mins  |
March 2024
Championing PAY PARITY
BioSpectrum Asia

Championing PAY PARITY

Despite women's significant strides and contributions in the healthcare field, they are paid less than men. Unfortunately, as is the case in most spheres, persistent pay disparities plague the life sciences sector. How big is the gender pay gap in the pharma industry? Are companies and the industry doing enough to address this issue? Let's find out.

time-read
6 mins  |
March 2024
ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES
BioSpectrum Asia

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES

Globally, women constitute 46 per cent of the workforce in the public sector, whereas in the private sector, they represent 33 per cent. The public sector maintains a higher representation of women as employees compared to the private sector as per data from the World Bank.

time-read
10+ mins  |
March 2024
US FDA approves first medication to treat severe frostbite
BioSpectrum Asia

US FDA approves first medication to treat severe frostbite

The US Food and Drug Administration (FDA) has approved Eicos Sciences Inc’s Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

time-read
1 min  |
March 2024
Japanese startup RevolKa to create highly functional proteins by using AI-driven platform
BioSpectrum Asia

Japanese startup RevolKa to create highly functional proteins by using AI-driven platform

RevolKa, a venture-backed biotech startup providing a gamechanging protein engineering technology platform, based in Japan, has signed a contract research agreement with Sekisui Chemical.

time-read
1 min  |
March 2024
Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development
BioSpectrum Asia

Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development

Taiwan-based startup Anbogen Therapeutics, a clinical-stage biotechnology company specialising in groundbreaking cancer drug development, has announced the successful completion of its Series A funding round.

time-read
1 min  |
March 2024
Samsung Biologics & LegoChem Biosciences team up for ADC development
BioSpectrum Asia

Samsung Biologics & LegoChem Biosciences team up for ADC development

South Korea-based Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has signed a partnership agreement with LegoChem Biosciences, a Korean biotech company pioneering the research and development of antibody-drug conjugate (ADC) programmes.

time-read
1 min  |
March 2024